Abstract
AKT (or protein kinase B) and focal adhesion kinase (FAK) are two important kinases that regulate various cellular functions. Each is overexpressed and/or aberrantly activated in diverse cancers. Several small molecular inhibitors targeting either AKT or FAK are in development or in clinical trials. It is well established that FAK is an upstream regulator of AKT signaling pathway in various cancer cell lines and in xenograft tumor models. However, very recent reports from our laboratory and others demonstrate that AKT can also directly regulate FAK through direct association and serine phosphorylation. This indicates that AKT and FAK may be dual therapeutic targets for pharmacologic intervention in the treatment of primary and metastatic cancer. FAK-AKT interaction is particularly critical for metastatic adhesion. We review recent developments in AKT and FAK signaling in cancer with the particular emphasis on the novel signaling pathways in which FAK is downstream of AKT. We also provide an update on inhibitors targeting AKT or FAK currently in clinical trials.
Keywords: AKT, AKT1, AKT2, cancer, cancer metastasis, cell signaling, differentiation, FAK, FERM, invasion, isoform, migration, proliferation, Src
Anti-Cancer Agents in Medicinal Chemistry
Title: Protein Kinase B/AKT and Focal Adhesion Kinase: Two Close Signaling Partners in Cancer
Volume: 11 Issue: 10
Author(s): Shouye Wang and Marc D. Basson
Affiliation:
Keywords: AKT, AKT1, AKT2, cancer, cancer metastasis, cell signaling, differentiation, FAK, FERM, invasion, isoform, migration, proliferation, Src
Abstract: AKT (or protein kinase B) and focal adhesion kinase (FAK) are two important kinases that regulate various cellular functions. Each is overexpressed and/or aberrantly activated in diverse cancers. Several small molecular inhibitors targeting either AKT or FAK are in development or in clinical trials. It is well established that FAK is an upstream regulator of AKT signaling pathway in various cancer cell lines and in xenograft tumor models. However, very recent reports from our laboratory and others demonstrate that AKT can also directly regulate FAK through direct association and serine phosphorylation. This indicates that AKT and FAK may be dual therapeutic targets for pharmacologic intervention in the treatment of primary and metastatic cancer. FAK-AKT interaction is particularly critical for metastatic adhesion. We review recent developments in AKT and FAK signaling in cancer with the particular emphasis on the novel signaling pathways in which FAK is downstream of AKT. We also provide an update on inhibitors targeting AKT or FAK currently in clinical trials.
Export Options
About this article
Cite this article as:
Wang Shouye and D. Basson Marc, Protein Kinase B/AKT and Focal Adhesion Kinase: Two Close Signaling Partners in Cancer, Anti-Cancer Agents in Medicinal Chemistry 2011; 11 (10) . https://dx.doi.org/10.2174/187152011797927661
DOI https://dx.doi.org/10.2174/187152011797927661 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Application of Functional Genomics to Bronchial Asthma
Current Pharmacogenomics Development of Amino Acid-Based Radiopharmaceuticals for Tumor Imaging
Mini-Reviews in Medicinal Chemistry From the Design to the Clinical Application of Thromboxane Modulators
Current Pharmaceutical Design Keeping A Breast of Recent Developments in Cancer Metabolism
Current Drug Targets Computer Modeling of Brain Tumor Growth
Mini-Reviews in Medicinal Chemistry Adenosine A1 Receptors in the Central Nervous System: Their Functions in Health and Disease, and Possible Elucidation by PET Imaging
Current Medicinal Chemistry Regulatory Effects of N-3 PUFAs on Pancreatic β-cells and Insulin-sensitive Tissues
Current Drug Metabolism Using Nutrigenomics to Evaluate Apoptosis as a Preemptive Target in Cancer Prevention
Current Cancer Drug Targets Patents Review in siRNA Delivery for Pulmonary Disorders
Recent Patents on Drug Delivery & Formulation Serotonin and Cancer: What Is the Link?
Current Molecular Medicine A Systemic Approach to Cancer Treatment: Tumor Cell Reprogramming Focused on Endocrine-Related Cancers
Current Medicinal Chemistry Hitting the Golden TORget: Curcumin’s Effects on mTOR Signaling
Anti-Cancer Agents in Medicinal Chemistry GPR55 and its Interaction with Membrane Lipids: Comparison with Other Endocannabinoid-Binding Receptors
Current Medicinal Chemistry Preoperative Functional Magnetic Resonance Imaging (fMRI) and Transcranial Magnetic Stimulation (TMS)
Current Medical Imaging Small Peptide and Protein-based Molecular Probes for Imaging Neurological Diseases
Current Protein & Peptide Science EGFR Transactivation by Peptide G Protein-Coupled Receptors in Cancer
Current Drug Targets MicroRNAs in Cancer: Small Molecules, Big Chances
Anti-Cancer Agents in Medicinal Chemistry Advances in the Development of Anticancer HSP-based Vaccines
Current Medicinal Chemistry Hypericin - The Facts About a Controversial Agent
Current Pharmaceutical Design Fluorescein Fluorescence Use in the Management of Intracranial Neoplastic and Vascular Lesions: A Review and Report of a New Technique
Current Drug Discovery Technologies